Trial Profile
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Cytarabine; Filgrastim; Fludarabine; Idarubicin; Pegfilgrastim
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 15 Aug 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2025.
- 15 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2025.
- 13 Dec 2022 Updated results (n=33) of phase IIb cohort were presented at the 64th American Society of Hematology Annual Meeting and Exposition.